Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
SUPN

SUPN - Supernus Pharmaceuticals Inc Stock Price, Fair Value and News

30.23USD+1.13 (+3.88%)Market Closed

Market Summary

SUPN
USD30.23+1.13
Market Closed
3.88%

SUPN Stock Price

View Fullscreen

SUPN RSI Chart

SUPN Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

6.3K

Price/Sales (Trailing)

2.83

EV/EBITDA

18.09

Price/Free Cashflow

16.03

SUPN Price/Sales (Trailing)

SUPN Profitability

EBT Margin

0.34%

Return on Equity

0.03%

Return on Assets

0.02%

Free Cashflow Yield

6.24%

SUPN Fundamentals

SUPN Revenue

Revenue (TTM)

586.9M

Rev. Growth (Yr)

-6.58%

Rev. Growth (Qtr)

-6.65%

SUPN Earnings

Earnings (TTM)

265.0K

Earnings Growth (Yr)

-99.27%

Earnings Growth (Qtr)

100.78%

Breaking Down SUPN Revenue

Last 7 days

5.6%

Last 30 days

13.4%

Last 90 days

2.8%

Trailing 12 Months

-1.4%

How does SUPN drawdown profile look like?

SUPN Financial Health

Current Ratio

1.73

SUPN Investor Care

Shares Dilution (1Y)

0.91%

Diluted EPS (TTM)

-0.02

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2024586.9M000
2023668.5M634.0M610.5M0
2022601.3M630.1M659.0M667.2M
2021556.4M571.0M564.3M579.8M
2020402.3M424.3M477.3M520.4M
2019403.9M409.1M408.2M392.8M
2018335.1M358.8M381.4M408.9M
2017228.4M252.6M276.2M302.2M
2016162.9M178.9M196.3M215.0M
2015112.3M118.3M135.0M147.5M
201421.0M50.3M71.8M92.7M
20131.4M1.6M2.8M12.0M
2012679.3K555.7K432.0K1.5M
2011025.6M13.2M803.0K
200900037.9M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Supernus Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 21, 2024
bhatt padmanabh p.
acquired
366,622
25.3
14,491
sr. vp of ip, cso
Mar 21, 2024
bhatt padmanabh p.
sold
-511,677
35.31
-14,491
sr. vp of ip, cso
Mar 20, 2024
bhatt padmanabh p.
sold
-14,124
35.31
-400
sr. vp of ip, cso
Mar 20, 2024
bhatt padmanabh p.
acquired
10,120
25.3
400
sr. vp of ip, cso
Mar 19, 2024
bhatt padmanabh p.
acquired
312,809
25.3
12,364
sr. vp of ip, cso
Mar 19, 2024
bhatt padmanabh p.
sold
-436,573
35.31
-12,364
sr. vp of ip, cso
Mar 13, 2024
bhatt padmanabh p.
acquired
1,098,520
17.6141
62,366
sr. vp of ip, cso
Mar 13, 2024
bhatt padmanabh p.
sold
-2,104,290
33.741
-62,366
sr. vp of ip, cso
Mar 12, 2024
bhatt padmanabh p.
acquired
50,414
12.98
3,884
sr. vp of ip, cso
Mar 12, 2024
bhatt padmanabh p.
sold
-128,133
32.99
-3,884
sr. vp of ip, cso

1–10 of 50

Which funds bought or sold SUPN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
reduced
-19.04
-25,378
44,138
-%
Jul 19, 2024
First Horizon Advisors, Inc.
reduced
-9.39
-11,877
29,157
-%
Jul 19, 2024
Hennion & Walsh Asset Management, Inc.
added
6.54
-223,568
1,135,510
0.06%
Jul 19, 2024
China Universal Asset Management Co., Ltd.
reduced
-38.43
-185,036
172,778
0.02%
Jul 18, 2024
CAMPBELL NEWMAN ASSET MANAGEMENT INC
added
0.21
-317,983
1,167,000
0.09%
Jul 18, 2024
VALLEY NATIONAL ADVISERS INC
sold off
-100
-1,000
-
-%
Jul 18, 2024
FRANKLIN STREET ADVISORS INC /NC
unchanged
-
-148,000
539,000
0.04%
Jul 17, 2024
KBC Group NV
unchanged
-
-14,000
47,000
-%
Jul 16, 2024
SJS Investment Consulting Inc.
unchanged
-
-30.00
107
-%
Jul 16, 2024
Envestnet Portfolio Solutions, Inc.
sold off
-100
-313,403
-
-%

1–10 of 50

Are Funds Buying or Selling SUPN?

Are funds buying SUPN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SUPN
No. of Funds

Unveiling Supernus Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
8.51%
4,650,000
SC 13G/A
Feb 14, 2024
macquarie group ltd
5.01%
2,737,721
SC 13G
Feb 13, 2024
vanguard group inc
11.38%
6,214,731
SC 13G/A
Jan 19, 2024
blackrock inc.
19.0%
10,381,318
SC 13G/A
Feb 14, 2023
armistice capital, llc
8.06%
4,356,000
SC 13G/A
Feb 09, 2023
vanguard group inc
10.71%
5,789,960
SC 13G/A
Jan 23, 2023
blackrock inc.
17.8%
9,604,073
SC 13G/A
Feb 15, 2022
armistice capital, llc
7.8%
4,136,000
SC 13G/A
Jan 27, 2022
blackrock inc.
15.9%
8,451,022
SC 13G/A
Jan 26, 2022
blackrock inc.
15.9%
8,451,022
SC 13G/A

Recent SEC filings of Supernus Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
Jul 19, 2024
144
Notice of Insider Sale Intent
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 16, 2024
144
Notice of Insider Sale Intent
Jul 15, 2024
144
Notice of Insider Sale Intent
Jun 17, 2024
8-K
Current Report
Jun 17, 2024
S-8
Employee Benefits Plan
May 23, 2024
8-K
Current Report
May 09, 2024
8-K
Current Report

Peers (Alternatives to Supernus Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
372.4B
85.6B
6.23% -8.11%
9.68
4.35
5.68% 202.39%
318.7B
61.4B
-1.70% 16.00%
138.18
5.19
6.11% -82.30%
177.7B
29.5B
8.27% 42.04%
47.23
6.02
12.76% -52.47%
169.7B
35.0B
9.27% -18.55%
146.05
4.84
-26.40% -92.03%
90.4B
27.4B
14.93% -9.21%
186.63
3.29
1.51% -91.32%
18.9B
16.0B
-1.18% 98.47%
-38.18
1.18
7.23% 71.10%
MID-CAP
4.2B
1.7B
1.72% -22.30%
9.68
2.44
54.01% 364.56%
3.8B
4.6B
9.59% -20.45%
-495.71
0.84
-0.06% 94.55%
2.8B
9.0B
17.62% -20.65%
-6.13
0.31
10.01% -27.45%
1.9B
676.2M
-1.12% -37.39%
12.52
2.86
30.38% 66.04%
SMALL-CAP
1.4B
743.2M
5.33% 7.88%
-3.91
1.85
24.65% 80.36%
21.2M
1.3M
-1.08% -55.56%
-2.86
16.12
-98.14% -104.71%
14.8M
89.6M
11.54% -18.69%
-1.04
0.19
287.27% -129.41%
9.8M
21.5M
320.59% -52.65%
-1.26
0.46
66.16% 61.84%
322.9K
115.7M
-61.54% -97.23%
0
0
-2.22% -352.48%

Supernus Pharmaceuticals Inc News

Latest updates
MarketBeat37 hours ago

Supernus Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue-6.7%14415413615416717717015315914814113114415512795.0010010210585.00116
Costs and Expenses0.7%14714615314913317915915115311610711810199.0081.0066.0060.0062.0062.0060.0076.00
  S&GA Expenses4.6%87.0083.0087.0086.0074.0011210090.0010272.0070.0061.0057.0054.0048.0042.0034.0039.0040.0041.0037.00
  R&D Expenses10.0%25.0023.0024.0021.0018.0020.0016.0021.0031.0020.0015.0015.0018.0017.0022.0019.0020.0017.0017.0015.0030.00
EBITDA Margin-23.6%0.15*0.20*0.18*0.21*0.22*0.15*0.18*0.20*0.19*0.25*0.29*0.32*0.36*--------
Interest Expenses---1.002.00-2.962.002.002.00-14.976.005.006.00-15.146.006.006.00-12.106.005.001.00-3.37
Income Taxes-99.5%0.0026.00-16.30-7.9310.00-2.193.00-10.89-0.397.008.005.009.0013.0013.008.008.0011.0010.006.0013.00
Earnings Before Taxes-97.5%0.0010.00-17.139.0035.00-0.4411.0015.002.0029.0031.0011.0040.0053.0047.0029.0041.0040.0043.0024.0039.00
EBT Margin-94.3%0.00*0.06*0.04*0.08*0.09*0.04*0.09*0.13*0.13*0.20*0.24*0.27*0.32*--------
Net Income100.8%0.00-15.98-0.8317.0025.002.008.0026.002.0022.0024.006.0031.0040.0035.0022.0033.0029.0033.0018.0026.00
Net Income Margin-98.9%0.00*0.04*0.07*0.08*0.09*0.06*0.09*0.12*0.09*0.14*0.18*0.20*0.24*--------
Free Cashflow6.8%38.0036.00-19.0349.0027.0014.0072.003.0049.00-4.1146.0035.0032.00--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets2.1%1,3041,2781,2851,2931,7921,7031,6931,6951,6401,6891,5551,5731,5071,5041,5101,4911,1901,1601,1071,0641,025
  Current Assets10.4%544493449424883734664625569602668639586630552557557473427391420
    Cash Equivalents-15.5%63.0075.0095.0025.0058.0093.0011117311620321522425628920421122618111787.00123
  Inventory-3.0%75.0077.0083.0091.0091.0092.0083.0085.0089.0086.0060.0058.0050.0048.0042.0035.0024.0027.0026.0026.0027.00
  Net PPE-4.1%13.0014.0014.0014.0015.0015.00--17.0017.00--38.0038.0017.0018.0018.0017.0010.004.004.00
  Goodwill0%11711711711711711711711511511840.0078.0078.0078.0089.0088.00-----
Liabilities5.3%375356373373880816840854811873745787753759801825576565550541545
  Current Liabilities8.4%315290288253732688726736285315235283241245300269168161150144152
    LT Debt, Current-------401401-------------
    LT Debt, Non Current----------379-----------
Shareholder's Equity0.8%929922912920912886853841828816810786754745709666613595557523480
  Retained Earnings0.0%483483481497498481456454446380377356332326296256221200166138105
  Additional Paid-In Capital1.7%447439432424416408401390383434429424416409403399392388384379374
Shares Outstanding0%55.0055.0054.0054.0054.0054.0054.0053.0053.0053.0053.0053.0053.00--------
Float--------1,546---1,635---1,205---1,678-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations7.0%38,40135,875-18,87449,12627,56413,84171,1194,30248,763-4,11046,27436,20031,9335,59991,9518,91643,79137,65828,68732,99332,849
  Share Based Compensation-25.5%5,8977,9206,0886,3064,2614,9854,2974,0254,0364,0275,4764,3713,1214,4904,9623,9883,6233,9144,0223,2872,991
Cashflow From Investing-249.1%-51,62434,63460,296239,780-48,765-82,232-15,679-69,98776,130-5,704-80,894-71,44549,345-11,302-108,18035,43819,438-8,355-65,761-103,24634,330
Cashflow From Financing782.6%1,570-230-478,91680,1742,8296,4552,273-22,034-136,7401,3242,7492,2473,069-9791,43732.001,2632421,6407831,251
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SUPN Income Statement

2024-03-31
Condensed Consolidated Statements of Earnings - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues  
Total revenues$ 143,644$ 153,764
Costs and expenses  
Cost of goods sold[1]16,30923,460
Research and development24,93021,212
Selling, general and administrative86,51685,597
Amortization of intangible assets20,13719,966
Contingent consideration gain(1,095)(1,647)
Total costs and expenses146,797148,588
Operating earnings (loss)(3,153)5,176
Other income (expense)  
Interest and other income, net3,3965,346
Interest expense0(1,505)
Total other income (expense)3,3963,841
Earnings before income taxes2439,017
Income tax expense (benefit)119(7,931)
Net earnings$ 124$ 16,948
Earnings per share  
Basic (in dollars per share)$ 0.00$ 0.31
Diluted (in dollars per share)$ 0.00$ 0.29
Weighted average shares outstanding  
Basic (in shares)54,801,74854,380,947
Diluted (in shares)55,626,66362,454,204
Net product sales  
Revenues  
Total revenues$ 138,461$ 140,575
Royalty and licensing revenues  
Revenues  
Total revenues$ 5,183$ 13,189
[1]Excludes amortization of acquired intangible assets

SUPN Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets  
Cash and cash equivalents$ 63,401$ 75,054
Marketable securities234,335179,820
Accounts receivable, net147,734144,155
Inventories, net75,07977,408
Prepaid expenses and other current assets23,77216,676
Total current assets544,321493,113
Long-term marketable securities11,66216,617
Property and equipment, net12,96913,530
Intangible assets, net579,752599,889
Goodwill117,019117,019
Other assets38,36737,505
Total assets1,304,0901,277,673
Current liabilities  
Accounts payable and accrued liabilities86,40279,569
Accrued product returns and rebates167,226154,274
Contingent consideration, current portion51,37952,070
Other current liabilities9,5474,283
Total current liabilities314,554290,196
Contingent consideration, long-term9761,380
Operating lease liabilities, long-term32,99433,196
Deferred income tax liabilities, net19,50124,963
Other liabilities6,8996,422
Total liabilities374,924356,157
Commitments and contingencies (Note 15)
Stockholders’ equity  
Common stock, $0.001 par value; 130,000,000 shares authorized; 54,965,316 and 54,723,356 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively5555
Additional paid-in capital446,960439,493
Accumulated other comprehensive loss, net of tax(534)(593)
Retained earnings482,685482,561
Total stockholders’ equity929,166921,516
Total liabilities and stockholders’ equity$ 1,304,090$ 1,277,673
SUPN
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a product candidate in Phase II clinical trials for treating resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
 CEO
 WEBSITEsupernus.com
 INDUSTRYPharmaceuticals
 EMPLOYEES612

Supernus Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Supernus Pharmaceuticals Inc? What does SUPN stand for in stocks?

SUPN is the stock ticker symbol of Supernus Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Supernus Pharmaceuticals Inc (SUPN)?

As of Fri Jul 19 2024, market cap of Supernus Pharmaceuticals Inc is 1.66 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SUPN stock?

You can check SUPN's fair value in chart for subscribers.

What is the fair value of SUPN stock?

You can check SUPN's fair value in chart for subscribers. The fair value of Supernus Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Supernus Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SUPN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Supernus Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SUPN is over valued or under valued. Whether Supernus Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Supernus Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SUPN.

What is Supernus Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, SUPN's PE ratio (Price to Earnings) is 6.27 Thousand and Price to Sales (PS) ratio is 2.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SUPN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Supernus Pharmaceuticals Inc's stock?

In the past 10 years, Supernus Pharmaceuticals Inc has provided 0.127 (multiply by 100 for percentage) rate of return.